Syndax Pharmaceuticals, Inc. <SNDX.O>: UBS cuts target price to $33 from $37
SNDX•Related News
Cyprus's GDEV Q2 revenue falls on lower bookings
GDEV•
Hanover Insurance EVP Dennis Francis Kerrigan disposes of common shares worth $1.9 million
THG•
Latham Group enters new USD 375 million senior secured credit facility with Jefferies Finance as agent
SWIM•
MicroCloud Hologram acquires 140,268 MicroStrategy shares valued at USD 15.76 million via structured note settlement
HOLO•
Werewolf Therapeutics announces USD 150 million oversubscribed private placement of shares, pre-funded warrants
HOWL•